Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

MBX Biosciences, Inc. Common Stock MBX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$55.33
+68.6%

MBX Biosciences, Inc. Common Stock (MBX) is a Biotechnology company in the Healthcare sector, currently trading at $32.81. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is MBX = $55 (+68.6% upside).

Valuation: MBX trades at a trailing Price-to-Earnings (P/E) of -13.4 (S&P 500 average ~25).

Net income is $87M (loss), growing at -51.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $596,000 against $369M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 24.62 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $385M.

Analyst outlook: 4 / 4 analysts rate MBX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$55.33
▲ 68.64% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for MBX Biosciences, Inc. Common Stock, the average price target is $55.33, with a high forecast of $88.00, and a low forecast of $18.00.
Highest Price Target
$88.00
Average Price Target
$55.33
Lowest Price Target
$18.00

MBX SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 60/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MBX

✓
VALUE Pass
60/100
MBX trades at a trailing Price-to-Earnings (P/E) of -13.4 (S&P 500 average ~25). Forward PEG -0.35 — Peter Lynch undervalued (≤1.0). Trailing PEG 16.04. Analyst consensus target is $55, implying +67.6% from the current price $33. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
MBX: +0%/yr revenue is, -51.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet MBX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 24.62 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
MBX: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 4 / 4 analysts rate MBX as buy (100%). Analyst consensus target is $55 (+67.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range4.807-44.89
Volume450.66K
Avg Volume (30D)598.04K
Market Cap$1.1B
Beta (1Y)1.07
Share Statistics
EPS (TTM)-2.38
Shares Outstanding$36.51M
IPO Date2000-01-14
Employees43
CEOPeter Kent Hawryluk
Financial Highlights & Ratios
Gross Profit$-248K
EBITDA$-98.06M
Net Income$-86.97M
Operating Income$-98.06M
Total Cash$373.71M
Total Debt$596K
Net Debt$-74.69M
Total Assets$385.14M
Price / Earnings (P/E)-13.8
Analyst Forecast
1Y Price Target$55.00
Target High$88.00
Target Low$18.00
Upside+67.6%
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS55287L1017

Price Chart

Track all markets on TradingView
MBX
MBX Biosciences, Inc. Common Stock ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
4.81 52WK RANGE 44.89

People Also View

ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 MLTX
MLTX
MoonLake Immunotherapeutics
$18.78
+1.90%
 AVBP
AVBP
ArriVent BioPharma, Inc. Common Stock
$27.64
+3.17%
 IOVA
IOVA
Iovance Biotherapeutics, Inc.
$3.64
+5.20%
 MGTX
MGTX
MeiraGTx Holdings plc
$11.29
+17.24%
 ATXS
ATXS
Astria Therapeutics, Inc.
$12.58
+0.00%
 RGNX
RGNX
REGENXBIO Inc.
$9.30
+2.88%
 DNA
DNA
Ginkgo Bioworks Holdings, Inc.
$7.72
+15.57%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message